Gilead Finally Releases Price for Esteemed Coronavirus Drug Remdesivir; Can People Afford It?

Medicine & Technology Jun 29, 2020

The price for remdesivir is out, and Gilead Sciences says it could cost up to $2,340 per patient for most wealthy nations. Some patient advocates contend that the price should be less, considering its development and trials received aid from the U.S. government. Click the link above to learn more.

Gilead’s Remdesivir Prevents Lung Damage in Monkeys, Adding to Its Long List of Successful Findings

Jun 09, 2020

Gilead's drug for coronavirus, remdesivir, once again shows its potential after a clinical trial reveals that it prevents lung damage in monkeys. Additionally, the results of the trial showed that the monkeys had minimal damage to their lungs in comparison with the control group.

Next on Gilead's Agenda: Inhaled Remdesivir and Other User-Friendly Versions of the Drug

Jun 03, 2020

Gilead Sciences just finished its phase 3 trials for remdesivir, and the results have been positive. As for the next step, the company seeks to explore making inhaled versions of the drug for early treatment of COVID-19 as well as easier treatment at home.

Gilead's Trials on Remdesivir to End in May; Worries on Access to the Drug Now Arises

May 15, 2020

The trials for Gilead's remdesivir is said to end in May. With the drug only being used for COVID-19 patients under the emergency use authorization, many worry about their access to the drug that has proved to be helpful against the coronavirus. Click the link above to learn more.

Remdesivir First FDA-Approved Drug for COVID-19 Could Cost up to $4,500 Despite Costing Just $9.32 to Manufacture

May 07, 2020

Remdesivir is now finally the first drug to be approved by the US FDA to treat COVID-19. However, controversy has started regarding its price. Experts say that is could cost up to $4,500 despite requiring just $9.32 to make. Click the link to read more.

India's Patent Office Breaths New Life On The Production Of Hepatitis C Medication, Gilead Shot-Down In The Process

Jan 21, 2015

Hepatitis C is a life-or-death disease of the liver that's known to be prevalent in third-world countries. But, with a steep medication price, treatment is often times a luxury. But with new Indian-based pharmaceutical companies joining Gilead, that all may change in the near future.

Hep-C Treatment On a Budget - Why Prices are Plummeting

Dec 23, 2014

After months of waiting and anticipation, the hepatitis C treatment price wars are finally getting under way. Express Scripts, the largest pharmacy benefits manager in the U.S., has released a new treatment from AbbVie as its exclusive treatment for patients with genotype 1, the most common form of the chronic disease. This drug covers 75% of the estimated 3.2 million Americans who are infected. And this new drug will likely change the market for the hepatitis C treatments that are currently led by a pair of medications from Gilead Sciences which is likely to reach $20 billion in revenue next year thanks to demand for its treatments.

New HIV Drug Promises to Be Cheaper, With Less Side Effects

Nov 08, 2014

Gilead seeks approval for new HIV drug; promises to be cheaper, with less side effects.